IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 729 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   [PDF Not available] *
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   Abstract
   Introduction
   Material and Methods
   Results
   Discussion
   References

 Article Access Statistics
    Viewed3661    
    Printed51    
    Emailed3    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal

 


 
STUDIES
Year : 1995  |  Volume : 61  |  Issue : 5  |  Page : 284-287

Sequential clinico-histological studies in psoriasis following methotrexate therapy




Correspondence Address:
S Talwar


Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 20952990

Rights and PermissionsRights and Permissions

  Abstract 

Ten cases of psoriasis were studied to see the pattern of histological resolution and to evaluate clinico-histological correlation in psoriasis following weekly methotrexate therapy. Five sequential biopsies were taken in each patient. Scaling was first to regress followed by induration and erythema in 18, 26 and 35 days, respectively. Uniform granular layer appeared in 4 days, stratum corneum became orthokeratotic in 7 days, mitotic activity got restricted to basal layer in 7 days and rete ridges elongation was reduced to half in 11 days. Mild acanthosis, cellular infiltrate and vascular dilatation pesisted even after full clinical regression. Interestingly, 5 out of 10 biopsies revealed increase in cellular infiltrate and oedema after first methotrexate pulse


Keywords: Psoriasis, Histopathology, Methotrexate


How to cite this article:
Talwar S, Tiwari V D, Lakhtakia R, Panvelkar V. Sequential clinico-histological studies in psoriasis following methotrexate therapy. Indian J Dermatol Venereol Leprol 1995;61:284-7

How to cite this URL:
Talwar S, Tiwari V D, Lakhtakia R, Panvelkar V. Sequential clinico-histological studies in psoriasis following methotrexate therapy. Indian J Dermatol Venereol Leprol [serial online] 1995 [cited 2019 Aug 19];61:284-7. Available from: http://www.ijdvl.com/text.asp?1995/61/5/284/4241



  Introduction Top


Methotrexate is generally recognised as an effective drug in the treatment of psoriasis.[1],[2] In this study, a sequential clinico-histopathological assessment was undertaken in an attempt to correlate the significant alterations during the period of treatment and the temporal framework in which they occurred.


  Material and Methods Top


Ten new cases of extensive plaque psoriasis with average body area involvement of more than 40% were induced into the study. The cases selected were male with average age of 35 years having near similar constitution. All the cases were hospitalized during the period of study. Methotrexate was given orally in doses of 5 mg every 12 hours for three doses per week after proper evaluation of hepatic, renal and haematological function. Clinical examination was done daily for which erythema, induration and scaling were taken as assessment parameters. For histopathological examination well developed single large plaque on lower limb was selected and skirt biopsies were taken from this lesion before starting methotrexate, 4 and 6 days after first methotrexate pulse, 4 days after second methotrexate pulse and last biopay was performed from healed lesion with residual hyperpigmentation. In all, five biopsies were taken from the same lesion in each patient.


  Results Top


1. All the cases responded to therapy requiring an average of 82.50 mg of methotrexate (4-12 methotrexate pulses), Scaling was first to regress followed by induration and erythema [Table:1]. The lesion healed with hyperpigmentation in about 35 days.

2. Some of the classical changes described in psoriasis [3,4] were missing in some of the premethotrexate biopsies. Granular layer was present in patchy manner in 9 out of 10 pretreatment biopsies. This was evident in form of 1-2 cell layer thickness, specially in the interpapillary region. Patchy parakeratosis was evident in 3 out of 10 cases. Rete ridge enlargement was usually of 15-20 cell layer thickness while suprapapillary epidermis was of 3 cell layer thickness. Mitosis was seen in lower 3 epidermal cell layers. Dermal infiltrate was usually moderate and pradominantly lymphocytic. In one case good number of eosinophils were also seen. The detils of histologicl response following treatment [Table:2] are:

A. Changes in the epidermis

(a) Keratinisation and maturation: Parakeratosis, which was present in all the cases became patchy within 96 hours of the first dose and thereafter disappeared [Figure:1]. The granular layer, which was either absent or patchy also recovered rapidly and in all the cases was continuous by third biopsy.

(b) Epidermal proliferation: In the suprapapillary regions the thinning returned to normal on the sixth day and clubbing and rete ridges elongation reduced by the 6th day. However, in most cases the elongation (acanthosis) persisted even after clinical recovery. Mitosis too were normal by 4-6 days.

(c) Basal layer: Breach of the basal layer in the form of melanin incontinence was present in the initial biopsy in three cases whereas the last biopsy invariably showed hyporpigmentation.

B. Changes in the dermis:

The dilated blood vessels and oedema reduced slowly but occasionaly persisted. The dermal infiltrate was seen in the mid dermis too by the 4th biopsy. Interestingly, in half the cases it had increased while on treatment and persisted, even if reduced, at the end of treatment. In all cases lymphocytes were present but in one case eosinophils were seen though there was no evidence of blood eosinophilia. Polymorphs were seen occssionally.


  Discussion Top


The aetiopathogenesis of psoriatic lesions remains unclear. Studies of relapsing lesions following stoppage of treatment reveal the earliest changes to be endothelial alteration, followed by appearance of degranulating mast cells and then marked macrophage infiltration in the basal keratinocytes.[5] These changes procede the charactersitic opidermal changes.[4]

Methotrexate acts in psoriasis competitive inhibition of dihydrofolate reductase, inhibition of (5a-induced polymorphonuclear chemotaxis,[6] leucotrine-84) induced infiltration of granulocyte into psoriatic epidermis,[7] and immunosuppressive effect.[8]

In the present study, the initial change noted uniformaly was the disappearance of parakeratosis and the reappearance of the granular layer, implying that it is the correction of the steps of abnormal maturation that seem to occur first. Whereas, the slower rate of recovery of the normal thickness of epidermis signifies that the actual rate of proliferation is controlled at a much slower rate. Thus, methotrexate probably acts on differentiation as well as by reducing proliferation rate.

Though melanin incontinence was present only in few cases, the process of recovery by hyperpigmentation appears to be a part of the normal healing process with incressed activity of the melanocytes.

Recovery of the vascular changes is slow and may account for the relapses where such lesions are not treated long enough, as according to some studies,[5] they appear to be the starting point for the entire lesion to develop.

Through methotrexate is known to suppress polymorphonuclear chemotaxis intraepidermally,[6] these cells have been found to appear while on treatment by some authors.[9] But, in this study, though these cells were seen only occasionally, the increase in density of the chronic inflammatory response appears to be favourable as it begins after the first pulse of therapy and though dininished, persists even later. The presence of eosinophils is an unusual feature which is difficult to explain.

This pilot study indicates that some features like reversion to orthokeratosis and appearance of granular layer may be the earliest and consistent signs of improvement. Likewise the persistance of vascular changes, acanthosis and dermal inflammation as noticed by other workers[10] may be taken to indicate that a histological assessment be made prior to labelling a case as clinically cured and switching over to maintainence therapy.

 
  References Top

1.Roenigk R, Auerbach R, Maiback H et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988:19:145-56.  Back to cited text no. 1    
2.Talwar S. Methotraxate-PUVASOL combination in treatment of psoriasis/Ind J Dermatol Venereol Leprol 1992;58:25-9.  Back to cited text no. 2    
3.Lever WF, Lever GS. In: Histopathology of the Skin, 7th edn. USA: JB Lipincott Company 1989,156-64.  Back to cited text no. 3    
4.Ragaz A, Ackerman AB. Evolution, maturation and regression of lesions of psoriasis. Am J Dermatopathol 1979;1:199-214.  Back to cited text no. 4  [PUBMED]  
5.Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 1985;277:352-8.  Back to cited text no. 5  [PUBMED]  
6.Ternewitz T, Bjerring P, Anderson P, et al. Methotrexate inhibitis the human C5a-induced skin response in psoriasis patients. J Invest Dermatol 1987;89:192-6.  Back to cited text no. 6    
7.Van de Kerkhof P, Bauef F, Grooth RM. Methotrexate inhibits leukotrione B4-induced intraepidermal accumulation of polymorphonuclear leukocytes. Br J Dermatol 1985;113:215a-255a.  Back to cited text no. 7    
8.Epstein W, Mailback H. Immunologic competence of patients with psoriasis receiving cytotoxic drug therapy. Arch Dermatol 1965;91:599-606.  Back to cited text no. 8    
9.Moller H. Reactivation of acute inflammation by methotrexate, J Invest Dermatol 1969;52:437-41.  Back to cited text no. 9  [PUBMED]  
10.Lal S, Sadana SR, Chitkara NL. Histopathology of psoriasis at various stages. Ind J Dermatol Venereol Leprol 1965;31:216-22.  Back to cited text no. 10    




 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow